Gene: LYPD6B

130576
CT116|LYPD7
LY6/PLAUR domain containing 6B
protein-coding
2q23.2
Ensembl:ENSG00000150556 Vega:OTTHUMG00000153743 UniprotKB:Q8NI32
NC_000002.12
PubMed|SNP Mapped
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.677e-1 (AD)  4.332e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs10201643chr2:149049127 (GRCh38.p7)T>Galcohol dependenceSNV(Single Nucleotide Variation)
rs16822509chr2:149038210 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TAC30.776
DLX10.761
PTHLH0.759
BTBD110.751
VIP0.739
GRIK10.722
CYGB0.711
ZNF385D0.709
ARL4C0.709
GAD10.707

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OTUD7B-0.475
KIF19-0.456
TRPV5-0.446
AQP1-0.434
VRK2-0.43
SNHG18-0.429
BAZ1A-0.415
DOCK5-0.415
TGFB3-0.414
C10orf105-0.411

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of LYPD6B mRNA"27291303
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD6B mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD6B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD6B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD6B mRNA"27188386
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of LYPD6B mRNA22316170
C006780bisphenol Abisphenol A results in decreased expression of LYPD6B mRNA26364221
C006780bisphenol Abisphenol A results in decreased expression of LYPD6B mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of LYPD6B gene28505145
D002737ChloropreneChloroprene results in increased expression of LYPD6B mRNA23125180
D003300CopperCopper results in decreased expression of LYPD6B mRNA18579281
D003471CuprizoneCuprizone results in decreased expression of LYPD6B mRNA26577399
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of LYPD6B mRNA23640034
C039281furanfuran results in increased expression of LYPD6B mRNA25539665
C492448ICG 001ICG 001 results in decreased expression of LYPD6B mRNA26191083
C029938nickel sulfatenickel sulfate results in increased expression of LYPD6B mRNA22714537
D052638Particulate MatterParticulate Matter results in decreased expression of LYPD6B mRNA23085030
C101814perfluoro-n-undecanoic acidperfluoro-n-undecanoic acid results in increased expression of LYPD6B mRNA23602845
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD6B mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of LYPD6B mRNA26272509
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of LYPD6B mRNA22714537
D011441PropylthiouracilPropylthiouracil affects the expression of LYPD6B mRNA24780913
D012906SmokeSmoke results in decreased expression of LYPD6B mRNA20015843
C017947sodium arsenitesodium arsenite results in increased expression of LYPD6B mRNA22714537
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to LYPD6B promoter]19654925
C009495titanium dioxidetitanium dioxide affects the expression of LYPD6B mRNA23557971
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of LYPD6B mRNA20133372
D014212TretinoinTretinoin results in increased expression of LYPD6B mRNA21934132
C012589trichostatin Atrichostatin A results in increased expression of LYPD6B mRNA24935251|2670570
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYPD6B mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of LYPD6B mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of LYPD6B gene25560391
C088658zoledronic acidzoledronic acid results in increased expression of LYPD6B mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0030548acetylcholine receptor regulator activity-IDA26586467  
GO ID GO Term Qualifier Evidence PubMed
GO:0099601regulation of neurotransmitter receptor activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005886plasma membrane-TAS-  
GO:0031225anchored component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-163125Post-translational modification: synthesis of GPI-anchored proteinsTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26586467The prototoxin LYPD6B modulates heteromeric alpha3beta4-containing nicotinic acetylcholine receptors, but not alpha7 homomers. (2016 Mar)Ochoa VFASEB J